Anchor Therapeutics has entered into a collaborative pharma partners agreement with Kyowa Hakko Kirin to utilize Anchor’s proprietary pepducin technology to advance KHK’s internal G protein-coupled receptor drug discovery portfolio.
This pharma partners agreement takes advantage of Anchor’s expanded business strategy to offer its pepducin technology for use as in vitro and in vivo research tools, in addition to developing pepducin therapeutics.
Under the terms of the pharma partners agreement, Anchor and KHK will work jointly to discover and optimize pepducin research tools to further the molecular understanding of certain GPCR targets in the KHK portfolio.
Anchor will receive an upfront payment, research funding, and downstream milestones.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Big Pharma
Report: Partnering Deals and Alliances with Kyowa Hakko Kirin
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity